Fig 1: FGF-2 secretion from Sertoli cells supports ZIKV infection and persistence. (A–D) Sertoli cells were treated for 16-hours with anti-FGF2 antibody (A), recombinant human FGF2 (B), FGFR inhibitor BGJ398 (C) or Azithromycin (D) and then infected with ZIKV MR766 (MR) or PRVABC59 (PR) (MOI = 0.5). Cells were harvested 48-hours post-infection and viral replication was determined by qRT-PCR analyses of total RNA extracted from cells. (E) Sertoli cells persistently infected with ZIKV MR766 (MR) or PRVABC59 (PR) were treated with DMSO control, duramycin (0.1 uM), control antibody (10 µg/ml) or anti-FGF2 antibody (10 µg/ml) for 7-days and viral replication was determined by qRT-PCR analyses of total RNA extracted from cells. All values are expressed as mean ± standard error. *P < 0.05, **P < 0.01 (One-way ANOVA); N = 3.